MedTrace Logo

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 528

Last updated 2025-10-27

Study results available
· View outcomes & findings →

Summary

This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.

Conditions

Interventions

DRUG

Durvalumab

Participants will receive IV infusion of durvalumab as stated in arm description.

DRUG

Danvatirsen

Participants will receive IV infusion of danvatirsen as stated in arm description.

DRUG

Ceralasertib

Participants will receive oral tablet of ceralasertib as stated in arm description.

DRUG

Vistusertib

Participants will receive oral tablets of vistusertib as stated in arm description.

DRUG

Olaparib

Participants will receive oral tablets of olaparib as stated in arm description.

DRUG

Oleclumab

Participants will receive IV infusion of oleclumab as stated in arm description.

DRUG

Trastuzumab deruxtecan

Participants will receive IV infusion of trastuzumab deruxtecan as stated in arm description.

DRUG

Cediranib

Participants will receive oral tablets of cediranib as stated in arm description.

Sponsors & Collaborators

Principal Investigators

  • John Heymach, M.D, Ph.D · The University of Texas MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-18
Primary Completion
2024-09-13
Completion
2026-09-11
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Canada
  • France
  • Germany
  • Israel
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03334617 on ClinicalTrials.gov